ES2399689T3 - Composiciones activadoras de la lipoproteína lipasa que comprenden derivados de benceno - Google Patents

Composiciones activadoras de la lipoproteína lipasa que comprenden derivados de benceno Download PDF

Info

Publication number
ES2399689T3
ES2399689T3 ES08753022T ES08753022T ES2399689T3 ES 2399689 T3 ES2399689 T3 ES 2399689T3 ES 08753022 T ES08753022 T ES 08753022T ES 08753022 T ES08753022 T ES 08753022T ES 2399689 T3 ES2399689 T3 ES 2399689T3
Authority
ES
Spain
Prior art keywords
alkyl
phenyl
compounds
compound
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08753022T
Other languages
English (en)
Spanish (es)
Inventor
Irina Neagu
Michael Ohlmeyer
Vidyadhar M. Paradkar
Kurt W. Saionz
Koushi Iwata
Takashi Okamura
Tadao Shibutani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Otsuka Pharmaceutical Factory Inc
Original Assignee
Otsuka Pharmaceutical Co Ltd
Otsuka Pharmaceutical Factory Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd, Otsuka Pharmaceutical Factory Inc filed Critical Otsuka Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2399689T3 publication Critical patent/ES2399689T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ES08753022T 2008-05-14 2008-05-14 Composiciones activadoras de la lipoproteína lipasa que comprenden derivados de benceno Active ES2399689T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2008/059294 WO2009139076A1 (en) 2008-05-14 2008-05-14 Lipoprotein lipase-activating compositions comprising benzene derivates

Publications (1)

Publication Number Publication Date
ES2399689T3 true ES2399689T3 (es) 2013-04-02

Family

ID=40289240

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08753022T Active ES2399689T3 (es) 2008-05-14 2008-05-14 Composiciones activadoras de la lipoproteína lipasa que comprenden derivados de benceno

Country Status (16)

Country Link
US (2) US20110065728A1 (enExample)
EP (1) EP2280706B1 (enExample)
JP (1) JP5398743B2 (enExample)
KR (1) KR101492308B1 (enExample)
CN (1) CN102026637B (enExample)
AU (1) AU2008356303B2 (enExample)
BR (1) BRPI0822685A2 (enExample)
CA (1) CA2723455C (enExample)
DK (1) DK2280706T3 (enExample)
ES (1) ES2399689T3 (enExample)
MX (1) MX2010012429A (enExample)
PL (1) PL2280706T3 (enExample)
PT (1) PT2280706E (enExample)
TW (1) TWI409065B (enExample)
WO (1) WO2009139076A1 (enExample)
ZA (1) ZA201007319B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2394996T3 (pl) * 2009-02-04 2016-12-30 Związki fenyloimidazolowe
GB201302927D0 (en) 2013-02-20 2013-04-03 Cancer Therapeutics Crc Pty Ltd Compounds
GB201415573D0 (en) 2014-09-03 2014-10-15 Cancer Therapeutics Crc Pty Ltd Compounds
US10494376B2 (en) 2014-09-03 2019-12-03 Ctxt Pty. Ltd. Tetrahydroisoquinoline derived PRMT5-inhibitors
US10005792B2 (en) 2014-09-03 2018-06-26 Ctxt Pty. Ltd. Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors
CA2999852A1 (en) * 2015-09-29 2017-04-06 Oncotherapy Science, Inc. Bicyclic compound and use thereof for inhibiting suv39h2
EP4023640A1 (en) 2015-12-25 2022-07-06 Otsuka Pharmaceutical Factory, Inc. Phenylimidazole compound
GB201604030D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604027D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604031D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604029D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604020D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604022D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
EP3453706A1 (en) 2017-09-08 2019-03-13 Basf Se Pesticidal imidazole compounds

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH483276A (de) 1959-09-23 1969-12-31 Ciba Geigy Verwendung von 2-Phenyl-benzazolen als Schutzmittel vor ultravioletter Strahlung ausserhalb der Textilindustrie
US3669979A (en) 1967-12-14 1972-06-13 Gaf Corp Novel process for the production of 2-benzothiazolyl-phenol and derivatives thereof employing phosphorus trichloride as a catalyst
US3647812A (en) 1969-04-22 1972-03-07 Richard F Smith Halogenated 2(2'-hydroxyphenyl benzothiazoles
US3876791A (en) 1973-11-30 1975-04-08 Uniroyal Inc Control of acarids using certain benzothiazoles or benzothiazolines
PT77844B (en) 1982-12-27 1986-05-08 Lilly Co Eli Process for preparing substituted imidazopyrimidines -pyrazines and -triazines
DE3446778A1 (de) * 1984-12-21 1986-07-03 Dr. Karl Thomae Gmbh, 7950 Biberach Neue imidazoderivate, ihre herstellung und diese verbindungen enthaltende arzneimittel
US4714762A (en) * 1986-10-31 1987-12-22 Warner-Lambert Company Antiarteriosclerotic substituted benzimidazol-2-yl-and 3H-imidazo[4,5-b]pyridin-2-yl-phenoxy-alkanoic acids and salts and esters thereof
US5179117A (en) * 1991-12-20 1993-01-12 Du Pont Merck Pharmaceutical Company Antihypercholesterolemic 2-substituted imidazoles
JPH07291976A (ja) * 1994-04-27 1995-11-07 Otsuka Pharmaceut Factory Inc イミダゾ〔２，１−ｂ〕チアゾール誘導体
JP3477238B2 (ja) 1994-04-27 2003-12-10 株式会社大塚製薬工場 イミダゾ〔１，２−ａ〕ピリジン誘導体
PE27997A1 (es) 1994-04-29 1997-09-20 Lilly Co Eli Antagonistas de receptores de taquicininas
JPH10324688A (ja) 1997-03-21 1998-12-08 Takeda Chem Ind Ltd イミダゾピリジン誘導体およびその製造法
JP2001226358A (ja) * 1999-10-12 2001-08-21 Japan Tobacco Inc Ｌｐｌ活性増強剤
JP2001163861A (ja) 1999-12-07 2001-06-19 Nippon Soda Co Ltd ジフェニルイミダゾール化合物および農園芸用殺菌剤
US6596731B2 (en) 2001-03-27 2003-07-22 Hoffmann-La Roche Inc. Substituted imidazo[1,2-A] pyridine derivatives
JP2006182668A (ja) * 2004-12-27 2006-07-13 Dainippon Sumitomo Pharma Co Ltd 高脂質症、動脈硬化、および／またはメタボリックシンドローム治療剤
WO2006122546A1 (de) * 2005-05-18 2006-11-23 Forschungsverbund Berlin E.V. Nicht-peptidische inhibitoren der akap-pka-wechselwirkung
BRPI0707719A2 (pt) * 2006-02-10 2011-05-10 Summit Corp Plc uso de um composto ou de um sal farmaceuticamente aceitÁvel do mesmo
WO2008029152A2 (en) * 2006-09-08 2008-03-13 Summit Corporation Plc Treatment of duchenne muscular dystrophy
EP1964840A1 (en) * 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]pyridines and their use as pharmaceuticals
PL2394996T3 (pl) * 2009-02-04 2016-12-30 Związki fenyloimidazolowe

Also Published As

Publication number Publication date
DK2280706T3 (da) 2013-02-04
BRPI0822685A2 (pt) 2015-06-30
EP2280706A1 (en) 2011-02-09
WO2009139076A1 (en) 2009-11-19
TW200946116A (en) 2009-11-16
CA2723455C (en) 2015-04-28
JP5398743B2 (ja) 2014-01-29
AU2008356303A1 (en) 2009-11-19
TWI409065B (zh) 2013-09-21
US20130296342A1 (en) 2013-11-07
PL2280706T3 (pl) 2013-05-31
CN102026637A (zh) 2011-04-20
KR20110005886A (ko) 2011-01-19
KR101492308B1 (ko) 2015-02-11
MX2010012429A (es) 2010-12-21
CN102026637B (zh) 2012-12-12
HK1154777A1 (en) 2012-05-04
PT2280706E (pt) 2013-02-19
AU2008356303B2 (en) 2013-05-02
ZA201007319B (en) 2012-01-25
CA2723455A1 (en) 2009-11-19
JP2011520775A (ja) 2011-07-21
US8895599B2 (en) 2014-11-25
EP2280706B1 (en) 2013-01-02
US20110065728A1 (en) 2011-03-17

Similar Documents

Publication Publication Date Title
EP2280706B1 (en) Lipoprotein lipase-activating compositions comprising benzene derivatives
US20110112079A1 (en) Phosphodiesterase inhibitors
US20190308977A1 (en) Fused bicyclic compounds for the treatment of disease
JP2010518026A (ja) ナトリウムチャネルが介在する疾患または状態の治療に有用なピリドピリミジノン化合物
US20250382309A1 (en) Methods and materials for increasing transcription factor eb polypeptide levels
US20180282321A1 (en) Compound for treating or preventing hyperuricemia or gout
CN101531638A (zh) 用作雌激素相关受体调节剂的化合物及其应用
KR20170117030A (ko) 질환의 치료를 위한 융합된 비시클릭 화합물
US20160207893A1 (en) Novel calcium modulators
WO2018106907A1 (en) Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therary
PT2139881E (pt) Quinolinas e a sua utilização terapêutica
RU2727194C2 (ru) Гетероциклические соединения для лечения заболевания
US20200079782A1 (en) Fused bicyclic compounds for the treatment of disease
WO2010006496A1 (zh) 用作雌激素相关受体调节剂的化合物及其应用
KR20130044314A (ko) 제5형 포스포다이에스터라아제 억제용 화합물 및 그의 제조 방법
JP2007523871A (ja) ケモカイン受容体活性の７および８員複素環式シクロペンチルベンジルアミドモジュレーター
RU2466725C2 (ru) Композиции для активации липопротеинлипазы, включающие производные бензола
HK1154777B (en) Lipoprotein lipase-activating compositions comprising benzene derivatives
RU2838857C2 (ru) Способы и материалы для повышения уровней полипептида фактора транскрипции eb
HK40049146A (en) Fused bicyclic compounds for the treatment of disease
JPH09505081A (ja) ５−リポキシゲナーゼ阻害物質としてのイソキサゾリン化合物